From preclinical research to regulatory approval and clinical adoption, diagnostic testing underpins every stage of ADC ...
Pfizer has ended development of a B7-H4-directed antibody-drug conjugate (ADC), triggering a $1 billion impairment charge. | ...
Alphamab Oncology (Stock Code: 9966.HK) and CSPC Pharmaceutical Group Co., Ltd. ("CSPC") (Stock Code: 1093.HK) jointly announced that anti-HER2 biparatopic antibody-drug conjugate (ADC) JSKN003 has ...
ADC Therapeutics SA (NYSE: ADCT), a commercial-stage global leader and pioneer in the field of antibody drug conjugates (ADCs ...
Antibody Drug Conjugates Market Market Growth Fueled by Advancements in ADC Technology, Increased Demand for Targeted Cancer Therapies, and ...
January 2025 kicked off with a wave of impactful biotech deals, setting the stage for an exciting year of innovation.
Johnson & Johnson executive praises China's biotech innovation in oncology and immunology, highlighting potential future ...
Verywell Health on MSN3d
A New 'Missile' Drug Is Approved To Treat the Most Common Breast Cancer TypeThe FDA approved Datroway to treat metastatic or unresectable HR+/HER2- breast cancer in people who have tried standard chemo ...
Explore the potential of monoclonal antibodies in Alzheimer’s treatment, including breakthroughs and challenges in this ...
Shares of solid tumor concern Zymeworks Inc. have barely budged since the company obtained its first approval. Click here to read why ZYME stock is a Hold.
ABBV-154, an antibody-drug conjugate comprising adalimumab conjugated to a proprietary glucocorticoid receptor modulator, shows potential for extending flare-free periods in patients with ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback